Nicotinic Acid, Alone and in Combinations, for Reduction of Cardiovascular Risk

American Journal of Cardiology

Volumn 101, Issue 8 SUPPL. 1, 2008, Pages

  Brown, B Greg ^a   Zhao, Xue Qiao ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; RESIN; SIMVASTATIN;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DRUG INDICATION; DYSLIPIDEMIA; HIGH RISK POPULATION; HUMAN; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK REDUCTION; SYSTEMATIC REVIEW;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLOFIBRIC ACID; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; HYPERLIPIDEMIAS; NIACIN; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 41049090772     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.02.039     Document Type: Article

References (24)

1. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., Stone N.J., and Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44 (2004) 720-732
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
3. Shepherd J, Betteredge J, Van Gaal L, on behalf of a European Consensus Panel.
4. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 27 suppl (2004) S68-S71
5. Sacks F.M., and Expert Group on HDL Cholesterol. The role of high density lipoprotein (HDL) cholesterol on the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 90 (2002) 139-143
6. Berenson A. End of drug trial is a big loss for Pfizer (2006), New York Times A1 December 4
7. Brown B.G., Hinckley-Stukovsky K., and Zhao X.-Q. Simultaneous LDL-C-lowering and HDL-C-raising for optimum cardiovascular disease prevention with various drug classes, and their combinations. J Clin Lipidology 1 (2007) 77-87
8. Brown B.G., and Gotto A.M. Impact of management on stabilization of plaque and reduction of cardiovascular events. In: Fuster V., Topol E.J., and Nabel E.G. (Eds). Atherothrombosis and Coronary Artery Disease (2005), Lippincott Williams & Wilkins, Philadelphia, PA 153-164
9. Wilson P.W., Anderson K.M., and Castelli W.P. Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy. The Framingham Offspring Study. Am J Med 90 (1991) 11-16
10. Assman G., Cullen P., and Schulte H. The Munster Heart Study (PROCAM): results of follow-up at 8 years. Eur Heart J 19 suppl (1998) A2-A11
11. LaRosa J.C., He J., and Vupputuri S. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA 282 (1999) 2340-2346
12. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360 (2002) 7-22
13. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., Jacobs Jr. D.R., Bangdiwala S., and Tyroler H.A. High density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 (1989) 8-15
14. Pekkanen J., Linn S., Heiss G., Suchindran C.M., Leon A., Rifkind B.M., and Tyroler H.A. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 322 (1990) 1700-1707
15. Brown G., Albers J.J., Fisher L.D., Schaefer S.M., Lin J.T., Kaplan C., Zhao X.Q., Bisson B.D., Fitzpatrick V.F., and Dodge H.T. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323 (1990) 1289-1298
16. Phillips N.R., Waters D., and Havel R.J. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 88 (1993) 2762-2770
17. Pedersen T.R., Faergeman O., Kastelein J.J.P., Olsson A.G., Tikkanen M.J., Holme I., Larsen M.L., Bendiksen F.S., Lindahl C., Szarek M., Tsai J., and Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. JAMA 294 (2005) 2437-2445
18. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.-C., Gotto A.M., Greten H., Kastelein J.J.P., Shepherd J., Wenger N.K., and Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
19. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288 (2002) 2998-3007
20. Blankenhorn D.H., Nessim S.A., Johnson R.L., Sanmarco M.E., Azen S.P., and Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257 (1987) 3233-3240
21. Carlson L.A., and Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 223 (1988) 405-418
22. Accord Acronym (ACCORD) clinicaltrials.gov Accord #NCT 00000620
23. AIM-HIGH Acronym (AIM-HIGH) clinicaltrials.gov AIM-HIGH: #NCT 00120289
24. HPS2-THRIVE Acronym (HPS2-THRIVE) clinicaltrials.gov HPS2-THRIVE #NCT 00461360